ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
SEK 20.6
(-4.63%)
SEK 20.6
(-4.63%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.4 Million SEK | 67960.0% |
| 2022 | 5000.00 SEK | -99.89% |
| 2021 | 4.72 Million SEK | 660.02% |
| 2020 | -843 Thousand SEK | -108.08% |
| 2019 | 10.43 Million SEK | 70.56% |
| 2018 | 6.11 Million SEK | -19.56% |
| 2017 | 7.6 Million SEK | 130.57% |
| 2016 | 3.29 Million SEK | 0.0% |
| 2015 | - SEK | -100.0% |
| 2014 | 6.61 Million SEK | -0.75% |
| 2013 | 6.66 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -97 Thousand SEK | -116.7% |
| 2024 Q2 | -12.34 Million SEK | -12630.93% |
| 2023 Q2 | 937 Thousand SEK | -23.32% |
| 2023 Q4 | 581 Thousand SEK | -12.37% |
| 2023 FY | 3.4 Million SEK | 67960.0% |
| 2023 Q3 | 663 Thousand SEK | -29.24% |
| 2023 Q1 | 1.22 Million SEK | 441.34% |
| 2022 Q3 | -820 Thousand SEK | -928.28% |
| 2022 FY | 5000.00 SEK | -99.89% |
| 2022 Q4 | -358 Thousand SEK | 56.34% |
| 2022 Q2 | 99 Thousand SEK | -90.87% |
| 2022 Q1 | 1.08 Million SEK | -51.3% |
| 2021 Q3 | 2.48 Million SEK | 101.95% |
| 2021 Q1 | -928 Thousand SEK | 85.34% |
| 2021 Q2 | 1.22 Million SEK | 232.33% |
| 2021 FY | 4.72 Million SEK | 660.02% |
| 2021 Q4 | 2.22 Million SEK | -10.24% |
| 2020 Q2 | 1.7 Million SEK | -10.0% |
| 2020 Q1 | 1.89 Million SEK | -29.61% |
| 2020 Q3 | 1.89 Million SEK | 11.41% |
| 2020 FY | -843 Thousand SEK | -108.08% |
| 2020 Q4 | -6.32 Million SEK | -433.98% |
| 2019 Q4 | 2.68 Million SEK | 10.0% |
| 2019 Q1 | 1.54 Million SEK | 46.39% |
| 2019 FY | 10.43 Million SEK | 70.56% |
| 2019 Q3 | 2.44 Million SEK | -35.15% |
| 2019 Q2 | 3.76 Million SEK | 144.42% |
| 2018 Q1 | 1.6 Million SEK | 28.79% |
| 2018 FY | 6.11 Million SEK | -19.56% |
| 2018 Q3 | 1.33 Million SEK | -37.32% |
| 2018 Q2 | 2.12 Million SEK | 32.32% |
| 2018 Q4 | 1.05 Million SEK | -21.02% |
| 2017 Q1 | 3.06 Million SEK | 73.51% |
| 2017 Q3 | 1.56 Million SEK | -9.55% |
| 2017 Q4 | 1.24 Million SEK | -20.17% |
| 2017 FY | 7.6 Million SEK | 130.57% |
| 2017 Q2 | 1.72 Million SEK | -43.67% |
| 2016 Q4 | 1.76 Million SEK | 87.38% |
| 2016 Q2 | 587 Thousand SEK | -82.2% |
| 2016 FY | 3.29 Million SEK | 0.0% |
| 2016 Q1 | 3.29 Million SEK | 0.0% |
| 2016 Q3 | 943 Thousand SEK | 60.65% |
| 2015 FY | - SEK | -100.0% |
| 2014 FY | 6.61 Million SEK | -0.75% |
| 2013 FY | 6.66 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 102.118% |
| Ziccum AB (publ) | -23.28 Million SEK | 114.614% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 99.017% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 91.856% |
| Mendus AB (publ) | 28.48 Million SEK | 88.054% |
| Genovis AB (publ.) | 54 Million SEK | 93.698% |
| Intervacc AB (publ) | -13.79 Million SEK | 124.67% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -56.748% |
| Active Biotech AB (publ) | -1.67 Million SEK | 303.164% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 65.844% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 87.312% |
| Aptahem AB (publ) | 2.63 Million SEK | -29.36% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 199.474% |
| Kancera AB (publ) | -1.96 Million SEK | 273.181% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -4319.481% |
| Fluicell AB (publ) | 1.73 Million SEK | -95.8% |
| Saniona AB (publ) | 11.78 Million SEK | 71.115% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 166.504% |
| Biovica International AB (publ) | 6.87 Million SEK | 50.516% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 114.616% |
| AcouSort AB (publ) | 8.38 Million SEK | 59.435% |
| Xintela AB (publ) | 78 Thousand SEK | -4262.821% |
| Abliva AB (publ) | -35.66 Million SEK | 109.542% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 102.317% |
| Karolinska Development AB (publ) | 2.8 Million SEK | -21.233% |
| OncoZenge AB (publ) | 3000.00 SEK | -113333.333% |
| Amniotics AB (publ) | -1.93 Million SEK | 276.321% |
| 2cureX AB (publ) | -37.48 Million SEK | 109.078% |
| CombiGene AB (publ) | -21.29 Million SEK | 115.984% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 904.492% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 99.699% |
| Camurus AB (publ) | 1.58 Billion SEK | 99.785% |
| Corline Biomedical AB | 28.38 Million SEK | 88.009% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 102.773% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 109.888% |
| I-Tech AB | 27.56 Million SEK | 87.655% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 95.204% |
| Cyxone AB (publ) | 2.61 Million SEK | -30.333% |
| Biosergen AB | -456 Thousand SEK | 846.272% |
| Cantargia AB (publ) | -3.45 Million SEK | 198.609% |
| NextCell Pharma AB | -43.74 Million SEK | 107.779% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 137.013% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 69.666% |
| Nanologica AB (publ) | -76 Thousand SEK | 4577.632% |
| SynAct Pharma AB | -778 Thousand SEK | 537.404% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 1863.212% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 126.335% |
| Lipum AB (publ) | 53 Thousand SEK | -6320.755% |
| BioInvent International AB (publ) | 71.46 Million SEK | 95.238% |
| Alzinova AB (publ) | 19.87 Million SEK | 82.877% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 90.625% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -132.601% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 22786.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -105.247% |
| Simris Alg AB (publ) | 2 Million SEK | -69.557% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 195.056% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 90.384% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 424.404% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | -8.618% |